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Summary.-Experiments were undertaken with DMBA-induced mammary tumours
of the rat to determine the anti-tumour properties of a new and potent luteinizing
hormone-releasing hormone (LH-RH) agonist, [D-Ser(But) 6AzglylO]-LH-RH
(ICI 118630). Tumours were classified according to their oestrogen-receptor (ER)
content. Twice daily i.m. injections of either 5 ,ug or 0-5 ,ug ICI 118630 in saline were
as effective as ovariectomy or tamoxifen therapy in causing the regression of ER+
DMBA-induced mammary tumours. ER- mammary tumours showed a more
equivocal overall response to ICI 118630, some tumours progressing, others regress-
ing. About one-third of the ER+ tumours disappeared in the 20-day treatment period.
Those tumours which did regrow after the cessation of treatment proved to be
hormone-dependent. In addition to the inhibitory effects of the LH-RH agonist on
pre-existing tumours, ICI 118630 also reduced the total number of new tumours
formed during and after treatment.
ONE OF THE MOST IMPORTANT character-
istics of mammary tumours induced in
rats by dimethylbenz(a)anthracene (DM-
BA) is that most of them are hormone-
dependent and regress after removal of
the ovaries (Huggins et al., 1959), the
pituitary gland (Daniel & Pritchard, 1963)
or in response to anti-oestrogens (Nichol-
son & Golder, 1975). The tumour, there-
fore, represents a good model with which
drugs previously shown to interfere with
either the production or secretion of
ovarian or pituitary hormones can be
screened for anti-tumour activity.
The present report investigates the
anti-tumour properties of one such com-
pound, [D-Ser(But)6Azgly10]-luteinizing
hormone-releasing hormone (ICI 118630),
a new and potent luteinizing hormone-
releasing hormone (LH-RH) agonist
(Dutta et al., 1978a; Nicholson et al.,
1978). Administration of ICI 118630 at
high dose levels (0.5 and 5 jug twice daily)
in rats reduces plasma oestradiol levels
(Maynard & Nicholson, 1979) and de-
creases the weight of the uterus in both
human - chorionic -gonadotrophin -treated
(Dutta et al., 1978a) and untreated animals
(Maynard & Nicholson, 1979).
MATERIALS AND METHODS
Peptide.-ICI 118630 was synthesized by
solution methods (Dutta et al., 1978b) by
Dr A. S. Dutta, ICI Pharmaceuticals Divi-
sion, Macclesfield, England. The purity of
the sample was >95%, as assessed by paper
electrophoresis, thin-layer chromatography
and amino-acid analysis.
Animal.s.-Mammary tumours were in-
duced in virgin female Sprague-Dawley rats
(55±2 days old) by intubation with a single
dose of 20 mg DMBA in 1 ml sesame oil.
Animals were housed in groups of 5 in a
12 h light/12 h dark environment and fed
diet and water ad libitumn. After 5 weeks, the
rats were palpated for tumours at weekly
intervals and the size recorded as the mean
of 2 perpendicular diameters, one measured
across the greatest width. Tumour volume
was estimated using the formula 4f 7Tr3 where
r is the mean radius.
Treatments.-When tumours reached an
approximate volume of 1-76 cm3 (1-5 cmANTI-TUMOUR ACTIVITY OF LH-RH AGONIST
mean diameter) a small portion (100 mg) of
each tumour was removed under ether
anaesthesia and stored at-20°Cforoestrogen
receptor (ER) assay. The remainder of the
tumour was left in situ and the animals
divided into 6 groups which were treated for
20 days as follows:
Group (a), 11 animals bearing 18 tumours
received twice daily i.m. injections of 5 ,ug
ICI 118630 in saline (100 ,ul);
(b), 7 animals bearing 9 tumours received
twice daily injections of 0 5 jtg ICI 118630;
(c), 8 animals bearing 12 tumours received
twice daily injections of 0-05 ,ug ICI 118630;
(d), 7 animals bearing 13 tumours received
twice daily injections of saline;
(e), 9 animals bearing 12 tumours were ovari-
ectomized at Time 0 and given twice daily
injections of saline;
(f), 9 animals bearing 12 tumours received
daily i.m. injections of tamoxifen [trans
isomerof1-(p-/-dimethylaminoethoxyphenyl)
-1,2-diphenylbut-l-ene] (100 jug) in sesame
oil (100 pd).
After the injections had been completed,
regrowth oftumours was monitored at weekly
intervals. Animals bearing reactivated tu-
mours from Groups (a-c) and (f) were
ovariectomized when at least one tumour
per animal reached a tumour volume >8-2
cm3 (2.5 cm mean diameter).
The procedures for the estimation of the
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FIG. 1. Response of oestrogen-receptor-positive (ER+) mammary tumours to treatment with ICI
118630 and tamoxifen. 5 groups of animals were injected twice daily for 20 days with either
(a) 5 ,ug ICI 118630, (b) 0-5 /cg ICI 118630, (c) 0-05 ,ug ICI 118630, (d) saline or (e) saline after
ovariectomy. The 6th group (f) received daily i.m. injections of tamoxifen (100 ,ig/injection).
Tumou-ir growth patterns were recorded as changes in tumour volume.
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ER content of tumour biopsy specimens,
together with the method of radioimmuno-
assay for oestradiol, have been previously
described (Nicholson, et al., 1978; Maynard &
Nicholson, 1979). The protein content of
cytosol fractions was estimated using LowAry's
method.
RESULTS
All tumours used in the study were
classified according to their ER content.
ER+ tumours were defined as those
tumours containing oestrogen-binding
components in excess of 8 fmol/mg cytosol
protein (Nicholson et al., 1978). Using
this classification scheme, 780% of tumours
were ER+. Data from these tumours are
described in Figs. 1 and 2. The effects of
giving twice-daily injections of either
5 or 0 5 jug of ICI 118630 resemble the
effects of ovariectomy and tamoxifen
treatment in that each was followed by
a decrease in tumour volume (Fig. la, b, c
and f). Reducing the dose of ICI 118630
to 0 05 [kg decreased its capacity to pro-
mote substantial tumour regression.
Fig. 2 shows that after the cessation of
ICI 118630 treatment in Group (a)
(5 [kg twice daily) no further growth
was seen in 5 of the tumours (Fig. 2b).
Of the remaining 10 tumours, 2 showed
spectacular increases in tumour volume
during the next 20-day period. Tumours
which regrew after ICI 118630 treatment
retained their hormone dependency and
regressed after ovariectomy (Fig. 2c).
Similar results were seen with tumours
from Groups (b), (c) and (f) (not
illustrated).
The data in Fig. 3a show the growth
patterns of 7 ER- tumours during ICI
118630 (Groups (a) and (b) and tamoxifen
treatment (Group (f)). Five ofthe tumours
continued to grow during the treatment
period and 2 regressed. In the 3 instances
where ovariectomy occurred after the
cessation of treatment, a progressive
tumour growth pattern was maintained
(Fig. 3b). Duringthestudy 2fibroadenomas
were detected, both being unresponsive
to ICI 118630 treatment and ovariectomy
(not illustrated).
In addition to the above effects of
ICI 118630 on the growth of palpable
tumours, the compound also decreased the
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FIG. 2. Growth patterns of tumours in animals after cessation of ICI 118630 treatment. (a) Animals
bearing ER+ DMBA-induced mammary tumours were a(iministered 5 ,tg ICI 118630 twice daily
for 20 days. Results are the mean ± range of values shown in Fig. la. (b) Tumour regrowth after the
cessation of ICI 118630 treatment. (c) Secondary effects of ovariectomy on tumours growing after
drug withdrawal.
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(b) TABLE II.-Effect of 118630 and ovari-
ectomy on plasma oestradiol-17P levels
Group
(Control)
(ICI 118630)
(Ovariectomy)
D 0 10 20
Time (days)
FIG. 3.-Response ofER- mammary tumours
to treatment with ICI 118630 and tam-
oxifen. (a) Animals injected twice daily
for 20 days with 5 ,ug ICI 118630 (0),
or 05 jug ICI 118630 (0) or daily with
100 g tamoxifen (U). (b) On cessation
of treatment suitable animals were ovari-
ectomized.
number of new tumours formed during
treatment (Table I). The effect was ob-
vious at each of the 3 dose levels. When
treatment ceased, some growth of new
tumours did occur, however, although the
total number of tumours formed was less
than in the control group. Fig. 4a details
Dose/
injection No. of
(,g) animals
6
5 6
6
Mean plasma
oestradiol
levels (pg/ml)
(and range)
33-6 (124-60-7)
8-6 (3-4-15-0)
8-7 (3.5-24)
the growth patterns of newly formed
tumours after cessation of treatment in
Groups (a) and (b). Of the 11 tumours
examined, 9 were detected within 21 days
of drug withdrawal. In the 7 where ovari-
ectomy was possible, all newly developed
tumours were hormone-dependent (Fig.
4b). Similar results were seen in the
tamoxifen-treated group.
Twice-daily administration of 5 /tg ICI
118630 for 20 days significantly reduced
circulating oestradiol-17/3 levels intumour-
bearing animals (Table II). The results
were indistinguishable from those in
ovariectomized animals.
DISCUSSION
The results described in this paper
indicate that [D-Ser(But)6Azglyl0]-LH-
RH (ICI 118630) is a potent anti-tumour
agent in DMBA-induced mammary
tumours of the rat. Twice-daily adminis-
tration of ICI 118630 (0.5 or 5 ,g) is as
effective as ovariectomy or tamoxifen
(100 /tg daily) in eliciting 2 phenomena:
(1) decrease in the number of newly
formed tumours; (2) regression of pre-
existing tumours. In common with ovari-
ectomy (McGuire et al., 1971) and tamoxi-
fen therapy (Jordan, 1975; Nicholson
TABLE I.-Effect of ICI 118630, tamoxifen and ovariectomy on development of mammary
tumours
New tumours formed
- ~~~A
Group Treatment
a (ICI 118630)
b (ICI 118630)
c (ICI 118630)
d (Control)
e (Ovariectomy)
f (Tamoxifen)
Dose/injection
(4g)
5*0
0*5
0*05
100
No. of
animals
11
7
8
7
9
9
During After
treatment treatment
0
0
4
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2
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3
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FIG. 4.-Development of new tumours after ICI 118630 withdrawal. (a) Growth patterns of new
tumours after the cessation of ICI 118630 (5.0 jig, 0; or 0 5 jig, 0) treatment. (b) Response to
ovariectomy ofnew tumours.
et al., 1978) the LH-RH agonist acts
mainly on ER+ tumours. ER- tumours
showed an equivocal overall response to
ICI 118630 treatment. This information,
taken in conjunction with the observation
that ICI 118630 decreases plasma oestra-
diol levels, suggests that the compound
may act by eliciting chemical castration
and thus depriving the tumour tissue of
oestradiol.
Although attractive, the hypothesis
does not include a role for prolactin, a
hormone which has been implicated both
individually and synergistically with oes-
trogen in the growth of DMBA-induced
mammary tumours (Pearson et al., 1972;
Sinha et at., 1973). Recently, Danguy and
his colleagues (Danguy et al., 1977) have
suggested that the anti-tumour effects of
another LH-RH agonist, [D-leu6, des-gly
NH21O, Pro-ethylamide9]-LH-RH (A
43818) were mediated by reduction in the
supply of prolactin to the target tissue.
In their study, oestrogen secretion was
apparently not suppressed, since oestrous
cycles were still present.
In addition to the potent capacity of
ICI 118630 (5 ,tg twice daily) to cause
tumour regression of ER+ rat mammary
tumours, it is noteworthy that 5/16
tumours within the ICI 118630 treatment
group showed no regrowth on withdrawal
of the drug (Fig. 2b). Thus, within the
strict limitations of the experiment, the
LH-RH agonist "cured" several tumours.
Where tumours did regrow, they were
subsequently shown to be hormone-
dependent. Hormone dependency was also
characteristic ofnew tumours formed after
ICI 118630 treatment had stopped. Such
information suggests that the treatment
cannot destroy all tumour cells. A pool of
resting cells, immune to the lytic effects
ofthe treatment, yet capable ofproliferat-
ing and gaining hormone dependency in
the absence of the drug, might explain
this phenomenon. It will be of interest,
therefore, to determine whether longer
treatment might effect a higher "cure"
rate by destroying tumour cells as they
are processed through the resting phase
into an active hormone-dependent state.
In conclusion we have noted that the
LH-RH agonist ICI 118630 has extremely
potent anti-tumour properties in the rat.
The tumour responses produced by this
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compound are equal in magnitude to those
after either ovariectomy or tamoxifen
treatment. Since the latter two treatments
are well established in the therapy of
advanced breast cancer, it seems likely
that ICI 118630 may also have therapeutic
value.
We are grateful to ICI Ltd. Pharmaceutical
Division for the opportunity to study the LH-RH
analogue; to Mr B. G. Brownsey for hormone
assays; to Professor K. Griffiths for his constructive
criticism and advice; and to the Tenovus Organiza-
tion and ICI Ltd. for financial support.
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